Abstract
Alterations in brain connectivity provide early indications of neurodegenerative diseases like Alzheimer’s disease (AD). Here, we present a novel framework that integrates a Hidden Markov Model (HMM) within the architecture of a convolutional neural network (CNN) to analyze dynamic functional connectivity (dFC) in resting-state functional magnetic resonance imaging (rs-fMRI). Our unsupervised approach captures recurring connectivity states in a large cohort of subjects spanning the Alzheimer’s disease continuum, including healthy controls, individuals with mild cognitive impairment (MCI), and patients with clinically diagnosed AD. The framework successfully identified distinct brain states associated with different clinical stages of AD, demonstrating a progressive reduction in functional flexibility as disease severity increased. Specifically, we observed that patients with AD spend more time in brain states dominated by unimodal sensory networks, while healthy controls exhibited more transitions to polymodal, cognitively demanding states. Importantly, the fraction of time spent in each state correlated with cognitive performance and anatomical atrophy in key regions, providing new insights into the disease’s progression.
Our findings suggest that the disruption of dynamic connectivity patterns in AD follows a two-stage model: early compensatory hyperconnectivity is followed by a decline in connectivity organization. This framework offers a powerful tool for early diagnosis and monitoring of AD progression and may have broader applications in studying other neurodegenerative conditions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
https://fnih.org/our-programs/alzheimers-disease-neuroimaging-initiative-3-adni-3/
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Original data is from the ADNI 3 database Code data is available through github
https://fnih.org/our-programs/alzheimers-disease-neuroimaging-initiative-3-adni-3/
